𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Dry mass, DNA and non-histone protein determinations in lung cancer cells

✍ Scribed by Schieck, R. ;Taubert, G. ;Krug, H.

Publisher
Springer
Year
1987
Tongue
English
Weight
467 KB
Volume
19
Category
Article
ISSN
0018-2214

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Multidrug resistance-associated protein
Multidrug resistance-associated protein (MRP1) is overexpressed in DNA aneuploid carcinomatous cells in non-small cell lung cancer (NSCLC)
✍ HΓ©lΓ¨ne Doubre; DaniΓ¨le CΓ©sari; Alexa Mairovitz; CΓ©cile BΓ©nac; Sandra Chantot-Bas πŸ“‚ Article πŸ“… 2004 πŸ› John Wiley and Sons 🌐 French βš– 227 KB πŸ‘ 1 views

Resistance to chemotherapy is intrinsically present in most nonsmall-cell lung carcinomas (NSCLC). No parameter has yet been determined to predict the response to chemotherapy. However, MRP1 (multidrug resistance-associated protein) is suspected to play an important role in resistance to treatment.

Mitochondrial DNA mutation correlates wi
Mitochondrial DNA mutation correlates with stage progression and prognosis in non-small cell lung cancer
✍ Wataru Matsuyama; Masanori Nakagawa; Joeji Wakimoto; Yasunobu Hirotsu; Masaharu πŸ“‚ Article πŸ“… 2003 πŸ› John Wiley and Sons 🌐 English βš– 88 KB πŸ‘ 1 views

The optimal management of patients with nonsmall cell lung cancer (NSCLC) depends on the accuracy of appropriate staging strategies. The best approach for clinical staging, especially the evaluation of lymph node metastasis, continues to confound clinicians. A specific, less-invasive method to suppo

Quantitative analysis of p53 protein in
Quantitative analysis of p53 protein in non-small cell lung cancer and its prognostic value
✍ Michael A. Levesque; Mario D'Costa; Ernest H. Spratt; Mohammad M. Yaman; Elefthe πŸ“‚ Article πŸ“… 1998 πŸ› John Wiley and Sons 🌐 French βš– 99 KB πŸ‘ 2 views

Accumulation of mutant p53 protein occurs frequently in human malignancies, including 40-60% of non-small cell lung carcinomas. The implications of such p53 over-expression, usually assessed by immunohistochemical techniques, for the prognosis of lung cancer patients remain undetermined. In this stu